Susceptibility Test Methods: Viruses*

Max Q. Arens; Ella M. Swierkosz

doi:10.1128/9781555816728.ch110

Chapter 110 : Susceptibility Test Methods: Viruses *

Authors: Max Q. Arens, Ella M. Swierkosz

Content Type: Reference

Publication Year: 2011

Category: Clinical Microbiology

Book DOI: 10.1128/9781555816728

Chapter DOI: 10.1128/9781555816728.ch110

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Susceptibility Test Methods: Viruses * , Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap110-1.gif /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap110-2.gif

Abstract:

This chapter discusses the clinical situations in which antiviral resistance has emerged, thus necessitating in vitro susceptibility testing. It provides an overview of the phenotypic and genotypic susceptibility testing methods that have been employed to detect resistance. Persistent or worsening herpes simplex virus type 1 (HSV-1) or varicella zoster virus (VZV) infection while on acyclovir (ACV) may indicate drug resistance. Persistent or worsening human cytomegalovirus (HCMV) retinitis, pneumonitis, or colitis unresponsive to ganciclovir may also indicate drug-resistant virus. Monitoring for Human Immunodeficiency Virus type 1 (HIV-1) antiretroviral resistance is essential when beginning antiretroviral therapy (ART), for assessing failure of a particular regimen to suppress HIV replication and to test for cross-resistance to alternative antiretroviral drugs to aid in selection of appropriate salvage therapy. The plaque reduction assay (PRA) has been the "standard" method of antiviral susceptibility testing. A number of phenotypic assays are in use for testing of HIV-1 isolate susceptibility to nucleoside analog RT inhibitors. The major advantage of genotypic assays is the relatively rapid turnaround time compared to phenotypic assays. Multicenter studies were carried out to compare sequencing results among participating laboratories for detection of reverse transcriptase (RT) mutations. In this study, sequence concordance was high, even though different editing strategies were used by different labs, but 12% of the resistance mutations present in the 10 electronic files that were distributed and analyzed were not identified in some labs.

Citation: Arens M, Swierkosz E. 2011. Susceptibility Test Methods: Viruses * , p 1729-1743. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch110

Highlighted Text: Show | Hide

Full text loading...

References

/content/book/10.1128/9781555816728.chap110

1. Andersson, K. L.,, and R. T. Chung. 2009. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 49: S166– S173.

2. Angus, P.,, R. Vaughan,, S. Xiong,, H. Yang,, W. Delaney,, C. Gibbs,, C. Brosgart,, D. Colledge,, R. Edwards,, A. Ayres,, A. Bartholomeusz,, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125: 292– 297.

3. Arens, M. 2001. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J. Clin. Virol. 22: 11– 29.

4. Baldanti, F.,, M. R. Underwood,, S. C. Stanat,, K. K. Biron,, S. Chou,, A. Sarasini,, E. Silini,, and G. Gerna. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70: 1390– 1395.

5. Baldanti, F.,, M. R. Underwood,, C. L. Talarico,, L. Simoncini,, A. Sarasini,, K. K. Biron,, and G. Gerna. 1998. The Cys 607→Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob. Agents Chemother. 42: 444– 446.

6. Bean, B.,, C. Fletcher,, J. Englund,, S. N. Lehrman,, and M. N. Ellis. 1987. Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. Diagn. Microbiol. Infect. Dis. 7: 199– 204.

7. Beddows, S.,, S. Galpin,, S. H. Kazmi,, A. Ashraf,, A. Johargy,, A. J. Frater,, N. White,, R. Braganza,, J. Clarke,, M. McClure,, and J. N. Weber. 2003. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J. Med. Virol. 70: 337– 342.

8. Belshe, R. B.,, B. Burk,, F. Newman,, R. L. Cerruti,, and I. S. Sim. 1989. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis. 159: 430– 435.

9. Belshe, R. B.,, M. H. Smith,, C. B. Hall,, R. Betts,, and A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62: 1508– 1512.

10. Berkowitz, F. E.,, and M. J. Levin. 1985. Use of an enzymelinked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virus. Antimicrob. Agents Chemother. 28: 207– 210.

11. Beutner, K. R. 1995. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antivir. Res. 28: 281– 290.

12. Biron, K. K. 1991. Ganciclovir-resistant human cytomegalovirus isolates; resistance mechanisms and in vitro susceptibility to antiviral agents. Transplant. Proc. 23(Suppl. 3): 162– 167.

13. Biron, K. K.,, and G. B. Elion. 1980. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob. Agents Chemother. 18: 443– 447.

14. Biron, K. K.,, J. A. Fyfe,, S. C. Stanat,, L. K. Leslie,, J. B. Sorrell,, C. U. Lambe,, and D. M. Coen. 1986. A human cytomegalovirus mutant resistant to the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. USA 83: 8769– 8773.

15. Biron, K. K.,, S. C. Stanat,, J. B. Sorrell,, J. A. Fyfe,, P. M. Keller,, C. U. Lambe,, and D. J. Nelson. 1985. Metabolic activation of the nucleoside analog q-[2-hydroxy- 1-(hydroxymethyl)ethoxymethyl] guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82: 2473– 2477.

16. Boivin, G.,, S. Chou,, M. R. Quirk,, A. Erice,, and M. C. Jordon. 1996. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173: 523– 528.

17. Boyd, M. R.,, S. Safrin,, and E. R. Kern. 1993. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir. Chem. Chemother. 4(Suppl.1): 3– 11.

18. Boyer, P. L.,, H.-Q. Gao,, and S. H. Hughes. 1998. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42: 447– 452.

19. Braun, P., and F. Wiesman. 2007. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. Eur. J. Med. Res. 12: 463– 471.

20. Bright, R. A.,, M.-J. Medina,, X. Xu,, G. Perez-Oronoz,, T. R. Wallis,, X. M. Davis,, L. Povinelli,, N. J. Cox,, and A. I. Klimov. 2005. Incidence of adamantine resistance among influenza A (H3N2) viruses isolated worldwide from 1994-2005: a cause for concern. Lancet 366: 1175– 1181.

21. Centers for Disease Control and Prevention. 1999. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Morb. Mortal. Wkly. Rep. 48(RR14): 1– 9.

22. Centers for Disease Control and Prevention. 2009. Update: drug susceptibility of swine-orgin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly Rep. 58: 433– 435.

23. Chatis, P. A.,, and C. S. Crumpacker. 1992. Resistance of herpesviruses to antiviral drugs. Antimicrob. Agents Chemother. 36: 1589– 1595.

24. Chou, S.,, A. Erice,, M. C. Jordon,, G. M. Vercellotti,, K. R. Michels,, C. L. Talarico,, S. C. Stanat,, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171: 576– 583.

25. Chou, S.,, S. Guentzel,, K. R. Michels,, R. C. Miner,, and W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172: 239– 242.

26. Chou, S.,, G. Marousek,, S. Guentzel,, S. E. Follansbee,, M. E. Poscher,, J. P. Lalezari,, R. C. Miner,, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176: 786– 789.

27. Cingolani A.,, A. Antinori,, M. G. Rizzo,, R. Murri,, A. Ammassari,, F. Baldini,, S. Di Giambenedetto,, R. Cauda,, and A. De Luca. 2002. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 16: 369– 379.

28. Cirelli, R.,, K. Herne,, M. McCrary,, P. Lee,, and S. K. Tyring. 1996. Famciclovir: review of clinical efficacy and safety. Antivir. Res. 29: 141– 151.

29. Coen, D. M., and D. D. Richman,. 2007. Antiviral agents, p. 447– 485. In D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

30. Cole, N. L.,, and H. H. Balfour, Jr. 1987. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn. Microbiol. Infect. Dis. 6: 255– 261.

31. Cunningham, S.,, B. Ank,, D. Lewis,, W. Lu,, M. Wantman,, J. Dileanis,, J. B. Jackson,, P. Palumbo,, P. Krogstad,, and S. H. Eshelman. 2001. Performance of the Applied Biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence- based analysis of HIV-1 in pediatric plasma samples. J. Clin. Microbiol. 39: 1254– 1257.

32. Dankner, W. M.,, D. Scholl,, S. C. Stanat,, M. Martin,, R. L. Sonke,, and S. A. Spector. 1990. Rapid antiviral DNADNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28: 293– 298.

33. De Clercq, E. 1982. Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob. Agents Chemother. 21: 661– 663.

34. DeGruttola, V.,, L. Dix,, R. D’Aquila,, D. Holder,, A. Phillips,, M. Ait-Kaled,, J. Baxter,, P. Clevenbergh,, S. Hammer,, R. Harrigan,, D. Katzenstein,, R. Lanier,, M. Miller,, M. Para,, S. Yerly,, A. Zolopa,, J. Murray,, A. Patick,, V. Miller,, S. Castillo,, L. Pedneault,, and J. Mellors. 2002. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5: 41– 48.

35. Dekker, C.,, M. N. Ellis,, C. McLaren,, G. Hunter,, J. Rogers,, and D. W. Barry. 1983. Virus resistance in clinical practice. J. Antimicrob. Chemother. 12: 137– 152.

36. Delwart, E. L.,, H. Pan,, H. W. Sheppard,, D. Wolpert,, A. U. Neumann,, B. Korber,, and J. L. Mullins. 1998. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J. Virol. 71: 7498– 7508.

37. Demeter, L. M.,, R. D’Aquila,, O. Weislow,, E. Lorenzo,, A. Erice,. J. Fitzgibbon,, R. Shaker,, D. Richman,, T. M. Howard,, Y. Zhao,, E. Fisher,, D. Huang,, D. Mayers,, S. Sylvester,, M. Arens,, K. Sannerud,, S. Rasheed,, V. Johnson,, D. Kiritzkes,, P. Reichelderfer,, and A. Japour for the ACTG Sequencing Working Group. 1998. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. J. Virol. Methods 75: 93– 104.

38. Deyde, V. M.,, M. Okomo-Adhiambo,, T. G. Sheu,, T. R. Wallis,, A. Fry,, N. Dharan,, A. I. Klimov,, and L. V. Gubareva. 2009. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antivir. Res. 81: 16– 24.

39. Deyde, V. M.,, X. Xu,, R. A. Bright,, M. Shaw,, C. B. Smith,, Y. Zhang,, Y. Shu,, L. V. Gubareva,, N. J. Cox,, and A. I. Klimov. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196: 249– 257.

40. Drew, W. L.,, R. C. Miner,, D. F. Busch,, S. E. Follansbee,, J. Gullett,, S. G. Mehalko,, S. M. Gordon,, W. F. Owen, Jr.,, T. R. Matthews,, W. C. Buhles,, and B. DeArmond. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163: 716– 719.

41. Durant, J.,, P. Clevenbergh,, P. Halfon,, P. Delgiudice,. S. Porsin,, P. Simonet,, N. Montagne,, C. A. B. Boucher,, J. M. Schapiro,, and P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 353: 2196– 2199.

42. Englund, J. A.,, M. E. Zimmerman,, E. M. Swierkosz,, J. L. Goodman,, D. R. Scholl,, and H. H. Balfour, Jr. 1990. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann. Intern. Med. 112: 416– 422.

43. Erali, M.,, S. Page,, L. G. Reimer,, and D. R. Hillyard. 2001. Human immunodeficiency virus type 1 drug resistance test: a comparison of three sequence-based methods. J. Clin. Microbiol. 39: 2157– 2165.

44. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12: 286– 297.

45. Erice, A., 2000. Antiviral susceptibility testing, p. 271– 289. In G. A. Storch (ed.), Essentials of Diagnostic Virology. Churchill Livingstone, New York, NY.

46. Erice, A.,, S. Chou,, K. K. Biron,, S. C. Stanat,, H. H. Balfour, Jr.,, and M. C. Jordan. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320: 289– 293.

47. Erice, A.,, C. Gil-Roda,, J.-L. Perez,, H. H. Balfour, Jr.,, K. J. Sannerud,, M. N. Hanson,, G. Boivin,, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175: 1087– 1092.

48. Eshelman, S. H.,, J. Hackett, Jr.,, P. Swanson,, S. P. Cunningham,, B. Drews,, C. Brennan,, S. G. Devare,, L. Zekeng,, L. Kaptue,, and N. Marlowe. 2004. Performance of the Celera Diagnostics ViroSeq HIV-1 genotyping system for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J. Clin. Microbiol. 42: 2711– 2717.

49. Fattovich, G.,, G. McIntyre,, M. Thursz,, K. Coleman,, G. Giuliano,, A. Alberti,, H. C. Thomas,, and W. F. Carman. 1995. Hepatitis B virus precore/core variation and interferon therapy. Hepatology 22: 1355– 1362.

50. Fung, S. K., and A. S. F. Lok. 2004. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40: 790– 792.

51. Gadler, H. 1983. Nucleic acid hybridization for measurement of effects of antiviral compounds on human cytomegalovirus DNA replication. Antimicrob. Agents Chemother. 24: 370– 374.

52. Ghany, M. G.,, and E. C. Doo. 2009. Antiviral resistance and hepatitis B therapy. Hepatology 49: S174– S184.

53. Gilbert, C.,, and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49: 873– 883.

54. Gintowt, A. A.,, J. J. Germer,, P. S. Mitchell,, and J. D. C. Yao. 2005. Evaluation of the MagNA Pure LC used with the TRUGENE ™ HBV Genotyping Kit. J. Clin. Virol. 34: 155– 157.

55. Gubareva, L. V.,, L. Kaiser,, M. N. Matrosovich,, Y. Soo-Hoo,, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183: 523– 531.

56. Gubareva, L. V.,, M. N. Mastrosovich,, M. K. Brenner,, R. C. Bethell,, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 179: 1257– 1262.

57. Hanna, G. J., and R. T. D’Aquila. 2001. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin. Infect. Dis. 32: 774– 782.

58. Hantz, S.,, D. Michel,, A.-M. Fillet,, V. Guigonis,, G. Champier,, M.-C. Mazeron,, A. Bensman,, F. Denis,, T. Mertens,, A. Dehee,, and S. Alain. 2005. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Antimicrob. Agents Chemother. 49: 1580– 1583.

59. Harmenberg, J.,, B. Wahren,, and B. Oberg. 1980. Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology 14: 239– 244.

60. Hassain, M.,, S. Fung,, E. Libbrecht,, E. Sablon,, C. Cursaro,, P. Andreone,, and A. S. F. Lok. 2006. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J. Clin. Microbiol. 44: 1094– 1097.

61. Hayden, F. 2009. Developing new antiviral agents for influenza treatment; what does the future hold? Clin. Infect. Dis. 48( Suppl. 1): S3– S13.

62. Hayden, F. G.,, K. M. Cote,, and G. D. Douglas, Jr. 1980. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Agents Chemother. 17: 865– 870.

63. Hertogs, K.,, M.-P. De Bethune,, V. Miller,, T. Ivens,, P. Schel,, A. Van Cauwenberge,, C. Van Den Eynde,, V. Van Gerwen,, H. Azijn,, M. Van Houtte,, F. Peeters,, S. Staszewski,, M. Conant,, S. Bloor,, S. Kemp,, B. Larder,, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42: 269– 276.

64. Hill, E. L.,, M. N. Ellis,, and P. Nguyen-Dinh,. 1991. Antiviral and antiparasitic susceptibility testing, p. 1184– 1188. In A. Balows,, W. J. Hausler, Jr.,, K. L. Hermann,, H. D. Isenberg,, and H. J. Shadomy (ed.), Manual of Clinical Microbiology, 5th ed. American Society for Microbiology, Washington, DC.

65. Hill, E. L.,, G. A. Hunter,, and M. N. Ellis. 1991. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 35: 2322– 2328.

66. Hirsch, M. S.,, F. Brun-Vezinet,, R. T. D’Aquila,, S. M. Hammer,, V. A. Johnson,, D. R. Kiritzkes,, C. Loveday,, J. W. Mellors,, B. Clotet,, B. Conway,, L. M. Demeter,, S. Vella,, D. M. Jacobsen,, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society—USA Panel. JAMA 283: 2417– 2426.

67. Hirsch, M. S.,, B. Conway,, R. T. D’Aquila,, V. A. Johnson,, F. Brun-Vezinet,, B. Clotet,, L. M. Demeter,, S. M. Hammer,, D. M. Jacobsen,, D. R. Kuritzkes,, C. Loveday,, M. W. Mellors,, S. Vella,, and D. D. Richman. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society—USA Panel. JAMA 279: 1984– 1991.

68. Huang, D. D.,, S. H. Eshelman,, D. J. Brambilla,, P. E. Palumbo,, and J. W. Bremer. 2003. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J. Clin. Microbiol. 41: 3265– 3272.

69. Iversen, A. K.,, R. W. Shafer,, K. Wehrly,, M. A. Winters,, J. I. Mullins,, B. Chesebro,, and T. C. Merigan. 1996. Multidrug- resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70: 1086– 1090.

70. Jacobson, M. A.,, T. G. Berger,, S. Fikrig,, P. Cecherer,, J. W. Moohr,, S. C. Stanat,, and K. K. Biron. 1990. Acyclovirresistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 112: 187– 191.

71. Janssen, H. L. A.,, M. vanZonneveld,, H. Senturk,, S. Zeuzem,, U. S. Akarca,, Y. Cakaloglu,, C. Simon,, T. M. K. So,, G. Gerken,, R. A. deMan,, H. G. M. Niesters,, P. Zondervan,, B. Hansen, and S. W. Schalm. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 365: 123– 129.

72. Japour, A. J.,, D. L. Mayers,, V. A. Johnson,, D. R. Kuritzkes,, L. A. Beckett,, J.-M. Arduino,, J. Lane,, R. J. Black,, P. S. Reichelderfer,, R. T. D’Aquila,, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37: 1095– 1101.

73. Johnson, V.,, F. Brun-Vezinet,, B. Clotet,, H. F. Gunthard,, D. R. Kuritzkes,, D. Pillay,, J. M. Schapiro,, and D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1: December 2008. Top. HIV Med. 16: 138– 145.

74. Kantor, R.,, D. A. Katzenstein,, B. Efron,, A. P. Carvalho,, B. Wynhoven,, P. Cane,, J. Clarke,, S. Sirivichayakul,, M. A. Soares,, J. Snoeck,, C. Pillay,, H. Rudich,, R. Rodrigues,, A. Holguin,, K. Ariyoshi,, M. B. Bouzas,, P. Cahn,, W. Sugiura,, V. Soriano,, L. F. Brigido,, Z. Grossman,, L. Morris,, A.-M. Vandamme,, A. Tanuri,, P. Rhanuphak,, J. N. Weber,, D. Pillay,, P. R. Harrigan,, R. Camacho,, J. M. Schapiro,, and R. W. Shafer. 2005. Impact of HIV-1 subtype and antiviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2: 325– 337.

75. Kellam, P.,, and B. A. Larder. 1994. A recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents. Chemother. 38: 23– 30.

76. Kusumi, K.,, B. Conway,, S. Cunningham,, A. Berson,, C. Evans,, A. K. N. Iversen,, D. Colvin,, M. V. Gallo,, S. Coutre,, E. G. Shpaer,, D. V. Faulkner,, A. DeRonde,, S. Volkman,, C. Williams,, M. S. Hirsch,, and J. I. Mullins. 1992. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J. Virol. 66: 875– 885.

77. Lai, C.-L.,, N. Leung,, E.-K. Teo,, M. Tong,, F. Wong,, H.-W. Hann,, S. Han,, T. Poynard,, M. Myers,, G. Chao,, D. Lloyd,, N. A. Brown, and the Telbivudine Phase II Investigator Group. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129: 528– 536.

78. Landry, M. L.,, S. Stanat,, K. Biron,, D. Brambilla,, W. Britt,, J. Jokela,, S. Chou,. W. L. Drew,, A. Erice,, B. Gilliam,, N. Lurain,, J. Manischewitz,, R. Miner,, M. Nokta,, P. Reichelderfer,, S. Spector,, A. Weinberg,, B. Yen-Lieberman,, C. Crumpacker, and the AIDS Clinical Trials Group CMV Resistance Working Group. 2000. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. J. Clin. Microbiol. 44: 688– 692.

79. Larder, B. A.,, G. Darby,, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731– 1734.

80. Leary, J. J.,, R. Wittrock,, R. T. Sarisky,, A. Weinberg,, and M. J. Levin. 2002. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob. Agents Chemother. 46: 762– 768.

81. Lehrman, S. N.,, J. M. Douglas,, L. Corey,, and D. W. Barry. 1986. Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. Ann. Intern. Med. 104: 786– 790.

82. Little, S. J.,, S. Holte,, J. Routy,, E. S. Daar,, M. Markowitz,, A. C. Collier,, R. A. Koup,, J. W. Mellors,, E. Connick,, B. Conway,, M. Kilby,, L. Wang,, J. M. Whitcomb,, N. S. Hellmann,, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347: 385– 394.

83. Lok, A. S. F. 2007. Navigating the maze of hepatitis B treatments. Gastroenterology 132: 1586– 1594.

84. Lok, A. S. F.,, and B. J. McMahon. 2007. Chronic hepatitis B: AASLD practice guidelines. Hepatology 45: 507– 539.

85. Lu, J.,, S. G. Deeks,, R. Hoh,, G. Beatty,, B. A. Kuritzkes,, J. N. Martin,, and D. R. Kuritzkes. 2006. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 43: 60– 64.

86. Lurain, N. S.,, K. D. Thompson,, E. W. Holmes,, and G. S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that results in resistance to antiviral agents. J. Virol. 66: 7146– 7152.

87. Lurain, N. S.,, A. Weinberg,, C. S. Crumpacker,, and S. Chou. 2001. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob. Agents Chemother. 45: 2775– 2780.

88. MacArthur, R. D., and R. M. Novak. 2008. Maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 47: 236– 241.

89. Marschner, I. C.,, A. C. Collier,, R. W. Combs,, R. T. D’Aquila,, V. DeGruttola,, M. A. Fischl,, S. M. Hammer,, M. D. Hughes,, V. A. Johnson,, D. A. Katzenstein,. D. D. Richman,, L. M. Smeaton,, S. A. Spector,, and M. S. Saag. 1998. Uses of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. 177: 40– 47.

90. Martin, J. L.,, M. N. Ellis,, P. M. Keller,, K. K. Biron,, S. N. Lehrman,, D. W. Barry,, and P. A. Furman. 1985. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates. Antimicrob. Agents Chemother. 28: 181– 187.

91. Martinez-Picado, J.,, A. V. Savara,, L. Sutton,, and R. T. D’Aquila. 1999. Replicative fitness of protease inhibitorresistant mutants of human immunodeficiency virus type 1. J. Virol. 73: 3744– 3752.

92. Martinez-Picado, J.,, L. Sutton,, M. P. De Pasquale,, A. V. Savara,, and R. T. D’Aquila. 1999. Human immunodeficiency virus type 1 cloning vectors for antiviral resistance testing. J. Clin. Microbiol. 37: 2943– 2951.

93. McLaren, C.,, M. N. Ellis,, and G. A. Hunter. 1983. A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. Antiviral Res. 3: 223– 224.

94. Moore, J. P.,, and D. R. Kuritzkes. 2009. A pièce de resistance: how HIV-1 escapes small molecular CCR5 inhibitors. Curr. Opin. HIV AIDS 4: 118– 124.

95. Moscona, A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360: 953– 956.

96. Mracna, M.,, G. Becker-Pergola,, J. Dileanis,, L. A. Guay,, S. Cunningham,, J. B. Jackson,, and S. H. Eshleman. 2001. Performance of Applied Biosystems ViroSeq HIV-1 genotyping system for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J. Clin. Microbiol. 39: 4323– 4327.

97.NCCLS. 2004. Antiviral Susceptibility Testing: Herpes Simplex Virus by Plaque Reduction Assay; Approved standard. NCCLS M33-A. NCCLS, Wayne, PA.

98. Olivero, A.,, A. Ciancio,, M. L. Abate,, S. Gaia,, A. Smedile,, and M. Rizzetto. 2006. Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations. J. Viral Hepat. 13: 355– 362.

99. Orito, E.,, M. Mizokami,, H. Sakugawa,, K. Michitaka,, K. Ishikawa,, and T. Ichida. 2001. A case-controlled study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Hepatology 33: 218– 223.

100. Osiowy, C.,, and E. Giles. 2003. Evaluation of the INNOLiPA HBV Genotyping assay for determination of hepatitis B virus genotype. J. Clin. Microbiol. 41: 5473– 5477.

101. Osiowy, C.,, J.-P. Villeneuve,, E. J. Heathcote,, E. Giles,, and J. Borlang. 2006. Detection of the rtN236T and rt181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J. Clin. Microbiol. 44: 1994– 1997.

102. Pahwa, S.,, K. Biron,, W. Lim,, P. Swenson,, M. H. Kaplan,, N. Sadick,, and R. Pahwa. 1988. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 260: 2879– 2882.

103. Pepin, J.-M.,, F. Simon,, M. C. Dazza,, and F. Brun-Vezinet. 1992. The clinical significance of in vitro cytomegalovirus susceptibility to antiviral drugs. Res. Virol. 143: 126– 128.

104. Perez, E. E.,, S. L. Rose,, B. Peyser,, S. L. Lamers,. B. Burkhardt,, B. M. Dunn,, A. D. Hutson,, J. W. Sleasman,, and M. M. Goodenow. 2001. Human immuno-deficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. J. Infect. Dis. 183: 579– 588.

105. Petropoulos, C. J.,, N. T. Parkin,, K. L. Limoli,, Y. S. Lie,, T. Wrin,, W. Huang,, H. Tian,, D. Smith,, G. A. Winslow,, D. J. Capon,, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42: 920– 928.

106. Rabalaiss, G. P.,, M. J. Levin,, and F. E. Berkowitz. 1987. Rapid herpes simplex virus susceptibility testing using an enzyme-linked immunosorbent assay performed in situ on fixed virus-infected monolayers. Antimicrob. Agents Chemother. 31: 946– 948.

107. Reeves, J. D.,, E. Coakley,, C. J. Petropoulos,, and J. M. Whitcomb. 2009. An enhanced sensitivity Trofile™ HIV coreceptor tropisms assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 3: 94– 102.

108. Richman, D. D. 1995. Clinical significance of drug resistance in human immunodeficiency virus. Clin. Infect. Dis. 21( Suppl. 2): S166– S169.

109. Richman, D. D.,, J. C. Guatelli,, J. Grimes,, A. Tsiatis,, and T. R. Gingeras. 1991. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus utilizing the polymerase chain reaction. J. Infect. Dis. 164: 1075– 1081.

110. Safrin, S.,, T. Assaykeen,, S. Follansbee,, and J. Mills. 1990. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J. Infect. Dis. 161: 1078– 1084.

111. Safrin, S.,, T. G. Berger,, I. Gilson,, P. R. Wolfe,, C. B. Wofsy,, J. Mills,, and K. K. Biron. 1991. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicellazoster virus infection. Ann. Intern. Med. 115: 19– 21.

112. Safrin, S.,, C. Crumpacker,, P. Chatis,, R. Davis,, R. Hafner,, J. Rush,, H. A. Kessler,, B. Landry,, J. Mills, and the AIDS Clinical Trials Group. 1991. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N. Engl. J. Med. 325: 551– 555.

113. Safrin, S.,, E. Palacios,, and B. J. Leahy. 1996. Comparative evaluation of microplate enzyme-linked immunosorbent assay versus plaque reduction assay for antiviral susceptibility testing of herpes simplex virus isolates. Antimicrob. Agents Chemother. 40: 1017– 1019.

114. Schinazi, R. F.,, B. A. Larder,, and J. W. Mellors. 1997. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 5: 129– 134.

115. Schuurman, R.,, D. Brambilia,, T. de Groot,, D. Huang,, S. Land,, J. Bremer,, I. Benders,, and C. A. Boucher. 2002. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retrovir. 18: 243– 248.

116. Schuurman, R.,, L. Demeter,, P. Reichelderfer,, J. Tijnagel,, T. DeGroot,, and C. Boucher. 1999. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 37: 2291– 2296.

117. Shafer, R. W. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15: 247– 277.

118. Shafer, R. W.,, D. R. Jung,, and B. J. Betts. 2000. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat. Med. 6: 1290– 1292.

119. Shamliyan, T. A.,, R. MacDonald,, A. Shaukat,, B. C. Tayor,, J.-M. Yuan,, J. R. Johnson,, J. Tacklind,. I. Rutks,, R. Kane,, and T. J. Wilt. 2009. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann. Intern. Med. 150: 111– 124.

120. Shaw, T.,, A. Bartholomeusz,, and S. Locarnini. 2006. HBV drug resistance: mechanisms, detection and interpretation. J. Hepatol. 44: 593– 606.

121. Shaw, T.,, and S. Locarnini. 2004. Entecavir for the treatment of chronic hepatitis B. Expert Rev. Anti-infect. Ther. 2: 853– 871.

122. Shi, C.,, and J. W. Mellors. 1997. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 41: 2781– 2785.

123. Sibrack, C. D.,, L. T. Gutman,, C. M. Wilfert,, C. McLaren,, M. H. St. Clair,, P. M. Keller,, and D. W. Barry. 1982. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J. Infect. Dis. 146: 673– 682.

124. Smith, I. L.,, J. M. Cherrington,, R. E. Jiles,, M. D. Fuller,, W. R. Freeman,, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176: 69– 77. (Erratum, 177: 1140– 1441, 1998.)

125. Spector, S. A.,, K. Hsia,, D. Wolf,, M. Shinkai,, and I. Smith. 1995=. Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Clin. Infect. Dis. 21( Suppl. 2): S170– S173.

126. Standring-Cox, R.,, T. H. Bacon,, and B. A. Howard. 1996. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir. J. Virol. Methods 56: 3– 11.

127. St. Clair, M. H.,, P. M. Hartigan,, J. C. Andrews,, C. L. Vavro,, M. S. Simberkoff,, J. D. Hamilton, and the VA Cooperative Study Group. 1993. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J. Acquir. Immune Defic. Syndr. 6: 891– 897.

128. St. Clair, M. H.,, J. L. Martin,, G. Tudor-Williams,, M. C. Bach,, C. L. Vavro,, D. M. King,, P. Kellam,, S. D. Kemp,, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557– 1559.

129. Swierkosz, E. M.,, and K. K. Biron,. 1994. Antiviral susceptibility testing, p. 8.26.2– 8.26.21. In H. D. Isenberg (ed.). Clinical Microbiology Procedures Handbook, supplement 1. American Society for Microbiology, Washington, DC.

130. Swierkosz, E. M.,, and K. K. Biron,. 1995. Antiviral susceptibility testing, p. 139– 154. In E. H. Lennette,, D. A. Lennette,, and E. T. Lennette (ed.), Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 7th ed. American Public Health Association, Washington, DC.

131. Swierkosz, E. M.,, D. R. Scholl,, J. L. Brown,, J. D. Jollick,, and C. A. Gleaves. 1987. Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus. Antimicrob. Agents Chemother. 31: 1465– 1469.

132. Tebas, P.,, D. Scholl,, J. Jollick,, K. McHarg,, M. Arens,, and P. D. Olivo. 1998. A rapid assay to screen for drug-resistant herpes simplex virus. J. Infect. Dis. 177: 217– 220.

133. Tebas, P.,, E. C. Stabel,, and P. D. Olivo. 1995. Antiviral susceptibility testing with a cell line which expresses b-galactosidase after infection with herpes simplex virus. Antimicrob. Agents Chemother. 39: 1287– 1291.

134. Tenney, D. J.,, S. M. Levine,, R. E. Rose,, A. W. Walsh,, S. P. Weinheimer,, L. Discotto,, M. Plym,, K. Pokornowski,, C. F. Yu,, P. Angus,, A. Ayres,, A. Bartholomeusz,, W. Sievert,, G. Thompson,, N. Warner,, S. Locarnini,, and R. J. Colonno. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents and Chemother. 48: 3498– 3507.

135. Tural, C.,, L. Ruiz,, C. Holtzer,, J. Schapiro,, P. Viciana,, J. Gonzalez,, P. Domingo,, C. Boucher,, C. Rey-Joly,, and B. Clotet. 2002. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16: 209– 218.

136. Valsamakis, A. 2007. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin. Microbiol. Rev. 20: 426– 439.

137. Van Laethem, K.,, and A.-M. Vandamme. 2006. Interpreting resistance data for HIV-1 therapy management-know the limitations. AIDS Rev. 8: 37– 43.

138. Walter, H.,, B. Schmidt,, K. Korn,, A. M. Vandamme,, T. Harrer,, and K. Uberla. 1999. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 13: 71– 80.

139. Wang, Y.,, L. Wei,, D. Jiang,, X. Cong,, R. Fei,, J. Xiao,, and Y. Wang. 2005. In vitro resistance to interferon of hepatitis B virus with precore mutation. World J. Gastroenterol. 11: 649– 655.

140. Wilson, J. W.,, P. Bean,, T. Robins,, F. Graziano,, and D. H. Persing. 2000. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J. Clin. Microbiol. 38: 3022– 3028.

141. Wolf, D. G.,, I. L. Smith,, D. J. Lee,, W. R. Freeman,, M. Flores-Aguilar,, and S. A. Spector. 1995. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J. Clin. Investig. 95: 257– 263.

142. Woo, H.-Y.,, H. Park,, B.-I. Kim,, W.-K. Jeon,, Y. K. Cho,, and Y. J. Kim. 2007. Comparison of mass spectrometric analysis and TRUGENE™ HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients. Antivir. Ther. 12: 7– 13.

143. Yuan, H.-J.,, and W. M. Lee. 2007. Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B. Curr. Mol. Med. 7: 185– 197.

144. Yuen, L. K. W.,, A. Ayres,, M. Littlejohn,, D. Colledge,, A. Edgely,, W. J. Maskill,, S. A. Locarnini,, and A. Bartholomeusz. 2007. SEQHEPB: a sequence analysis program and relational database for chronic hepatitis B. Antivir. Res. 75: 64– 74.

145. Zhang, J.,, S.-Y. Rhee,, J. Taylor,, and R. Shafer. 2005. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J. Acquir. Immune Defic. Syndr. 38: 439– 444.

Tables

Susceptibility Test Methods: Viruses*

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555816728.chap110-1,webId=/content/author/10.1128/9781555816728.chap110-1,properties={foaf_givenname=Max Q., foaf_name=Max Q. Arens, foaf_surname=Arens}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555816728.chap110-2,webId=/content/author/10.1128/9781555816728.chap110-2,properties={foaf_givenname=Ella M., foaf_name=Ella M. Swierkosz, foaf_surname=Swierkosz}]]

/content/10.1128/9781555816728.chap110.tab110-1

TABLE 1

Proposed guidelines for antiviral susceptibility results of herpes group and influenza A viruses

10.1128/9781555816728/tab110-1_thmb.gif

10.1128/9781555816728/tab110-1.gif

TABLE 1

Proposed guidelines for antiviral susceptibility results of herpes group and influenza A viruses